Leucine

Leucine

SCHEMBL466383

CC(C)C[C@H](N)C(=O)O.CC(C)[C@H](N)C(=O)O

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.78
SLC1A3 P43003 6/20 0.61
SLC1A2 P43004 6/20 0.61
SLC1A1 P43005 6/20 0.57
GRIK1 P39086 8/20 0.44
GRIK2 Q13002 5/20 0.44
GRM1 Q13255 1/20 0.43
GRM2 Q14416 1/20 0.43
RNPEP Q9H4A4 1/20 0.41
GRIA2 P42262 2/20 0.41
GRIA4 P48058 2/20 0.41
GRIK3 Q13003 2/20 0.41
GRIK5 Q16478 2/20 0.41
GRIA1 P42261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Leucine SCHEMBL17184327 1.00 SLC7A5 (0.78) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL4394463 1.00 SLC7A5 (0.78) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL4401591 1.00 SLC7A5 (0.78) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL375261 1.00 SLC7A5 (0.78) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL466382 1.00 SLC7A5 (0.78) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL28161805 1.00 SLC7A5 (0.78) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL17184328 1.00 SLC7A5 (0.78) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
D-Leucine SCHEMBL11768667 1.00 SLC7A5 (0.78) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL11305893 1.00 SLC7A5 (0.78) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
Leucine SCHEMBL2553000 0.96 SLC7A5 (0.72) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3716762-A1 METHOD FOR THE CRYOPRESERVATION OF CELLS FOR THERAPEUTIC PURPOSES Laboratoire Français du Fractionnement et des Biotechnologies (FR) 2020-10-07 EP claimed
US-10381112-B2 Method and system for characterizing allergy-related conditions associated with microorganisms uBiome, Inc. (US) 2019-08-13 US claimed
EP-3474849-A1 COMPOSITIONS AND METHODS FOR DETECTING AND TREATING DIABETES The Broad Institute, Inc. (US) 2019-05-01 EP claimed
WO-2018005445-A1 COMPOSITIONS AND METHODS FOR DETECTING AND TREATING DIABETES THE BROAD INSTITUTE, INC. (US) 2018-01-04 WO claimed
US-RE41287-E1 modulate the activity of G protein-coupled receptors and are useful in the treatment of conditions mediated by G protein-coupled receptors, for example, inflammatory conditions; rheumatoid arthritis PROMICS PTY LIMITED (AU) 2010-04-27 US claimed
US-20050197398-A1 Therapeutic agent for hepatic disease AJINOMOTO CO., INC (JP) 2005-09-08 US claimed
EP-1084137-A1 PEPTIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2001-03-21 EP claimed
WO-1999064442-A1 PEPTIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI S.P.A. (IT) 1999-12-16 WO claimed
US-5955340-A DNA CODING POLYPEPTIDE WITH ALTERED HEAT OXIDATION AND ALKALI RESISTANCE, SUBSTRATE SPECIFICITY AND ENZYME KINETICS GENENCOR INTERNATIONAL, INC. (US) 1999-09-21 US claimed
EP-0413528-B1 Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use YU RUEY J (US) 1995-11-15 EP claimed
WO-1992011286-A1 OXIDATION RESISTANT VARIANTS OF PARATHYROID HORMONE ALLELIX BIOPHARMACEUTICALS INC. (CA) 1992-07-09 WO claimed
EP-0115713-A1 2-(1-Piperazinyl)-pyrimidines, their salts, process for their preparation and pharmaceutical compositions containing them SANOFI S.A. (FR) 1984-08-15 EP claimed
CN-120129690-A Dual receptor targeted radioligands and uses thereof 辐联科技香港有限公司 2025-06-10 CN disclosed
CN-118326031-A System for identifying traditional Chinese medicine symptoms of rheumatoid arthritis through molecular markers 中国中医科学院中药研究所 2024-07-12 CN disclosed
WO-2024143514-A1 PURIFICATION METHOD AND PRODUCTION METHOD OF CYCLIC PEPTIDE 中外製薬株式会社 2024-07-04 WO disclosed
US-20240158865-A1 Markers of Triple-Negative Breast Cancer and Uses Thereof VANDERBILT UNIVERSITY 2024-05-16 US disclosed
WO-1991005564-A1 SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1991-05-02 WO disclosed
EP-0400010-A1 SOLUBLE HUMAN CD4 FRAGMENTS AND USES THEREFOR DANA-FARBER CANCER INSTITUTE (US) 1990-12-05 EP disclosed
WO-1989003222-A1 SOLUBLE HUMAN CD4 FRAGMENTS AND USES THEREFOR DANA-FABER CANCER INSTITUTE (US) 1989-04-20 WO disclosed
EP-0280673-A2 Method for production of inorganic minute globular particles Nippon Shokubai Kagaku Kogyo Co., Ltd (JP) 1988-08-31 EP disclosed